Astellas Announces Topline Results from Phase 3 Long-Term Safety Study of Fezolinetant in Mainland China
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced topline results from the Phase 3...
Source: prnewswire.com